---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-100714"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:18:37.044668+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics files new cross-claims in FDA suit challenging YUTREPIA NDA acceptance

## Summary
- On Sept. 16, 2024, United Therapeutics filed new cross-claims against FDA in the existing FDA Suit.
- Cross-claims re-assert challenge to FDA's acceptance of Liquidia's NDA for YUTREPIA (treprostinil).
- Liquidia states it will vigorously defend its ability to launch YUTREPIA and against the allegations.
- United had voluntarily dismissed a similar challenge on Aug. 20, 2024, before refiling as cross-claims.
- Liquidia's prior suit challenging FDA's 3-year NCI exclusivity for Tyvaso DPI remains ongoing.

## SEC filing metadata
- accession: 0001104659-24-100714
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924100714/0001104659-24-100714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924100714/tm2424262d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-100714
- JSON: https://secwatch.observer/filing/0001104659-24-100714.json
- Plain text: https://secwatch.observer/filing/0001104659-24-100714.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.